Funds from Pelotonia are helping the OSUCCC – James change the landscape of cancer care by supporting three statewide initiatives that promote early detection and better outcomes for patients with colorectal, lung and endometrial cancers in Ohio.
Ohio Prevention and Treatment of Endometrial Cancer (OPTEC)
A statewide clinical cancer research project called Ohio Prevention and Treatment of Endometrial Cancer (OPTEC), which is supported by $1.25 million in Pelotonia funds, aims to recruit up to 700 women with endometrial cancer from partner hospitals across the state and screen them for Lynch syndrome (LS) and other inherited genetic conditions linked to greater risk of endometrial, colorectal, stomach and ovarian cancers. Their tumor samples will undergo molecular profiling to identify targeted treatments personalized to each patient’s tumor characteristics. Patients identified with LS and their at-risk family members will be educated about the importance of genetic testing and cancer-prevention strategies based on their increased risk for LS-associated cancers.
Ohio Colorectal Cancer Prevention Initiative (OCCPI)
A five-year statewide initiative to screen newly diagnosed colorectal cancer patients and their biological relatives for Lynch syndrome has closed but will have far-reaching benefits by setting the stage for future LS screening in Ohio and around the nation. Funded over five years (2013-18) by $4.3 million from Pelotonia, the Ohio Colorectal Cancer Prevention Initiative (OCCPI) established a 50-hospital network to accommodate screenings for Lynch syndrome (LS), an inherited genetic condition that predisposes to colorectal, endometrial, ovarian, stomach and other cancers. The LS screenings identify patients and family members who may be at risk of developing these cancers so they can take precautionary measures, including heightened surveillance for early detection.
Beating Lung Cancer in Ohio (BLC-IO)
Recruitment continues for a statewide clinical research initiative taking aim at lung cancer, the number one cancer killer among men and women in the United States. Led by Peter Shields, MD, the initiative is called Beating Lung Cancer in Ohio (BLC-IO) and is supported by $3 million from Pelotonia. The initiative will draw upon a network of 50 hospitals around Ohio that was established by an earlier Pelotonia-funded statewide project. BLC-IO has two aims: to assess the impact of advanced gene testing and expert advice on lung cancer treatment and patient survival and to improve smoking-cessation rates among smokers with lung cancer and their family members.